Treatment comparisons for a partially categorical outcome applied to a biomarker with assay limit

Statistics in Medicine

Volumn 24, Issue 2, 2005, Pages 211-228

  Chen, Y H Joshua ^a   Gould, A Lawrence ^a   Nessly, Michael L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Assay limit; Biomarker; Censored outcome; HIV RNA; Limit of quantification; Partially categorical outcome

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; VIRUS RNA; ZIDOVUDINE;

ARTICLE; BIOASSAY; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PROGNOSIS; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RANK SUM TEST; SENSITIVITY ANALYSIS; SIMULATION; STATISTICAL ANALYSIS; VIRUS LOAD; WILCOXON SIGNED RANKS TEST;

ANTI-HIV AGENTS; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; DOUBLE-BLIND METHOD; HIV; HIV INFECTIONS; HUMANS; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS; RNA, VIRAL; STATISTICS, NONPARAMETRIC;

EID: 12344312472     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.1833     Document Type: Article

References (29)

1. Murray JS, Elashoff MR, Iacono-Connors LC, Cvetkovich TA, Struble KA. The use of plasma HIV-RNA as a study endpoint in efficacy trials of antiretroviral drugs. AIDS 1999; 13:797-804.
2. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, Kingsley LA, Todd JA, Saah AJ, Detels R, Phair JP, Rinaldo CR. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Annals of Internal Medicine 1997; 126:946-954.
3. Mellors JW, Rinaldo CR, Gupta P et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167-1170.
4. Hughes MD, Johnson VA, Hirsch MS et al. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. Annals of Internal Medicine 1997; 126:929-938.
5. Albert JM, Ioannidis JPA, Reichelderfer P et al. Statistical issues for HIV surrogate endpoints: point/counterpoint. Statistics in Medicine 1998; 17:2435-2462.
6. U.S. Food and Drug Administration 2002. Guidance for industry: antiretroviral drugs using plasma HIV-RNA measurements - clinical considerations for accelerated and traditional approval.
7. The European Agency for the Evaluation of Medical Products 2000. Points to consider in the assessment of an anti-HIV medical product.
8. Amplicor HIV-1 Monitor™ Test (Standard/UltraSensitive). Roche Diagnostic Systems, Inc. U.S. Food and Drug administration (FDA) Label, 1999.
9. Carpenter CCJ, Cooper DA, Fischl MA et al. Antiretroviral therapy in adults: updated recommendations of the international AIDS society - USA panel. Journal of the American Medical Association 2000; 283:381-390.
10. Squires KE, Gulick R, Tebas P et al. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naïve individuals with HIV infection: selection of thymidine analog regimen therapy (START I). AIDS 2000; 14:1591-1600.
11. Weiler H. A significance test for simultaneous quantal and quantitative responses. Technometrics 1964; 6: 273-285.
12. Marschner IC, Betensky RA, De Gruttola V, Hammer SM, Kuritzkes DR. Clinical trials using HIV-1 RNA-based primary endpoints: statistical analysis and potential biases. Journal of Acquired Immune Deficiency Syndrome Human Retrovirology 1999; 20:220-227.
13. Hughes MD. Analysis and design issues for studies using censored biomarker measurements with an example of viral load measurements in HIV clinical trials. Statistics in Medicine 2000; 19:3171-3191.
14. Henry SL. Maximum likelihood inference for left-censored HIV-RNA data. Statistics in Medicine 2001; 20: 33-45.
15. Tobin J. Estimation of relationships for limited dependent variables. Econometrica 1958; 26:24-36.
16. Moulton LH, Curriero FC, Barroso PF. Mixture models for quantitative HIV-RNA data. Statistical Methods in Medical Research 2002; 11:317-325.
17. Taylor DJ, Kupper LL, Rappaport SM, Lyles RH. A mixture model for occupational exposure mean testing with a limit of detection. Biometrics 2001; 57:681-688.
18. Journot V, Chene G, Joly P et al. Viral load as a primary outcome in human immunodeficiency virus trials: a review of statistical analysis methods. Controlled Clinical Trials 2001; 22:639-658.
19. Gehan EA. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 1965; 52 203-223.
20. Gould AL. A new approach to the analysis of clinical drug trials with withdrawals. Biometrics 1980; 36: 721-727.
21. Moye LA, Davis BR, Hawkins CM. Analysis of a clinical trial involving a combined mortality and adherence dependent interval censored endpoint. Statistics in Medicine 1992; 11:1705-1717.
22. Lachin JM. Worst-rank score analysis with informatively missing observations in clinical trials. Controlled Clinical Trials 1999; 20:408-422.
23. SAS Institute Inc. SAS/STAT User's Guide, Version 6 (4th edn), vol. 2. SAS Institute: Cary, NC, 1989.
24. Proc-StatXact™ for SAS Users. Cytel Software Corporation: Cambridge, MA, 1997.
25. Hollander M, Wolfe DA. Nonparametric Statistical Methods (2nd edn). Wiley: New York, 1999.
26. 3. Revue de l. Instituto de Medicina Tropical de Sao Paulo 2000; 42(1):27-36.
27. Susman E. Notes from the XIV international AIDS conference in Barcelona, Spain. AIDS 2002; 16(16): N11-N13.
28. Drusano GL, Bilello JA, Stein DS, Nessly ML, Meibohm A, Emini EA, Deutsch P, Condra J, Chodakewitz J, Holder DJ. Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables. Journal of Infectious Diseases 1998; 178:360-367.
29. Hallstrom AP, Litwin PE, Weaver WD. A method of assigning scores to the components of a composite outcome: an example from the MITI trial. Controlled Clinical Trials 1992; 13:148-155.